Literature DB >> 2580239

A hapten-specific chimaeric IgE antibody with human physiological effector function.

M S Neuberger, G T Williams, E B Mitchell, S S Jouhal, J G Flanagan, T H Rabbitts.   

Abstract

Immunoglobulin E (IgE) has a central role in allergic reactions although it rarely exceeds 5 micrograms ml-1 even in the serum of severely allergic individuals. Both mast cells and basophils possess receptors which bind the Fc portion of IgE with high affinity; crosslinking of membrane-bound IgE by allergen results in degranulation of the cell and release of a variety of pharmacologically active mediator including histamine. Myeloma IgE has been successfully used to block the skin sensitizing activity of allergic sera; however, human myeloma IgE is clearly in limited supply. The emergence of techniques allowing the stable introduction of immunoglobulin gene DNA into myeloma cells has allowed us to construct a mouse cell line that secretes a chimaeric IgE, lambda 1 antibody whose heavy chain is composed of a human C epsilon constant region fused to a mouse variable (VH) region. This chimaeric IgE is specific for the hapten 4-hydroxy-3-nitro-phenacetyl (NP) and can, when crosslinked by antigen, trigger the degranulation of human basophils. When not crosslinked, however, the chimaeric IgE can prevent the passive sensitization of these cells by sera from allergic subjects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580239     DOI: 10.1038/314268a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  63 in total

1.  Characterisation of a mouse monoclonal anti-idiotype reactive with a V region sequence commonly used by human immunoglobulins.

Authors:  J E McElveen; P B Furtado; S J Smith; M R Clark; I Spendlove; H F Sewell; F Shakib
Journal:  Mol Pathol       Date:  2000-04

2.  Endocytosis and recycling of the complex between CD23 and HLA-DR in human B cells.

Authors:  S N Karagiannis; J K Warrack; K H Jennings; P R Murdock; G Christie; K Moulder; B J Sutton; H J Gould
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

Review 3.  Adapting antibodies for clinical use.

Authors:  R E Hawkins; M B Llewelyn; S J Russell
Journal:  BMJ       Date:  1992-11-28

Review 4.  Clinical significance of anti-IgE autoantibodies and immune complexes containing IgE.

Authors:  C G Magnusson; S G Johansson
Journal:  Clin Rev Allergy       Date:  1989

Review 5.  Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.

Authors:  Jamie Campbell; David Lowe; Matthew A Sleeman
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 6.  Therapeutic antibodies: successes, limitations and hopes for the future.

Authors:  Patrick Chames; Marc Van Regenmortel; Etienne Weiss; Daniel Baty
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

7.  Unreliable measurement of basophil maximum leukotriene release with the Bühlmann CAST 2000 enzyme-linked immunosorbent assay kit.

Authors:  S E Burastero; C Paolucci; D Breda; G Monasterolo; R E Rossi; L Vangelista
Journal:  Clin Vaccine Immunol       Date:  2006-03

8.  A humanized antibody that binds to the interleukin 2 receptor.

Authors:  C Queen; W P Schneider; H E Selick; P W Payne; N F Landolfi; J F Duncan; N M Avdalovic; M Levitt; R P Junghans; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  Defining the complementarities between antibodies and haptens to refine our understanding and aid the prediction of a successful binding interaction.

Authors:  Mohammed M Al Qaraghuli; Soumya Palliyil; Gillian Broadbent; David C Cullen; Keith A Charlton; Andrew J Porter
Journal:  BMC Biotechnol       Date:  2015-10-24       Impact factor: 2.563

10.  Antibodies generated from human immunoglobulin miniloci in transgenic mice.

Authors:  S D Wagner; G T Williams; T Larson; M S Neuberger; D Kitamura; K Rajewsky; J Xian; M Brüggemann
Journal:  Nucleic Acids Res       Date:  1994-04-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.